In a recent clinical trial, more than half of the terminal cancer patients participating have experienced significant shrinking of their tumors, and in some cases, their complete disappearance. The new class of immunotherapy drugs appears likely to be a game changer for cancer sufferers. The research was announced at the recent annual conference of the American Society of Clinical Oncology where it was described as "spectacular."
